From AAVantgarde we want to send our warmest congratulations to our Founder and CSO, Prof. Alberto Auricchio, that has just been elected as President of ESGCT
AAVantgarde Bio
Biotechnology Research
Delivering the next generation gene therapies
About us
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
- Website
-
https://www.aavantgarde.com
External link for AAVantgarde Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
- Specialties
- Gene Therapy, Ophthalmology, and Rare diseases
Employees at AAVantgarde Bio
-
Michael Murtagh
-
Malcolm Horsley
Experienced Executive and Consultant | Board experience, interim roles, Non Exec roles
-
Alberto Auricchio
Scientific Director, Principal Investigator at TIGEM (Telethon Institute of Genetics and Medicine)
-
Doug Kerr MD, PhD, MBA
Scientist, physician, neurologist, neuroscientist, company-builder, entrepreneur and drug developer. Founding member of the gene therapy company…
Updates
-
We're #hiring a new Senior Medical Director - Ophthalmology in Greater London, England. Apply today or share this post with your network.
-
We're #hiring a new Principal Scientist Analytical Development - Gene Therapy AAV in London Area, United Kingdom. Apply today or share this post with your network.
-
We're #hiring a new Senior Scientist Process Development in England. Apply today or share this post with your network.
-
We're #hiring a new Principal Biostatistician (Ophthalmology) in Greater London, England. Apply today or share this post with your network.
-
We're #hiring a new Principal Biostatistician (Ophthalmology) in London Area, United Kingdom. Apply today or share this post with your network.
-
AAVantgarde team is attending AAO 2024 in Chicago (18-21 Oct)!! The AAVantgarde team, led by our CEO, Natalia Misciattelli, are attending the American Academy of Ophthalmology (AAO) Annual Meeting in Chicago from 18 – 21 October! 🎉 This prestigious event brings together leading experts, innovators, and professionals in the field of ophthalmology to discuss cutting-edge advancements, exchange knowledge, and explore the future of eye care. 🌟 With two clinical stage programs in MYO7A associated Retinitis Pigmentosa and Stargardt’s disease, our mission is to develop transformative solutions that restore vision and improve quality of life for Ophthalmology patients worldwide. Our passionate team of experts: CMO Jayashree Sahni, VP of Clinical Sciences and Safety Ali Memon, VP of Clinical Operations Joe Brennan, Director of Surgical Liaison Chantelle de Lima, and Head of Corporate Development Magda Blanco, are eager to connect with fellow professionals at AAO, and explore the latest innovations in ophthalmology. If you are attending AAO, please reach out to us. We’d love to connect! Let’s share insights and ideas to advance the future of eye care together. #Ophthalmology #AAO2024 #InnovationInEyeCare #GeneTherapy #IRDs
-
AAVantgarde Bio reposted this
We're #hiring a new Principal Scientist Gene Therapy / Transgene Design in England. Apply today or share this post with your network.